Ehsan Hamid, Wahab Ahsan, Anwer Faiz, Iftikhar Raheel, Yousaf Muhammad N
Biomedical Sciences/Biohazardous Threat Agents & Emerging Infectious Diseases, Georgetown University, Washington, USA.
Internal Medicine, MedStar Union Memorial Hospital, Baltimore, USA.
Cureus. 2020 Aug 27;12(8):e10070. doi: 10.7759/cureus.10070.
-thalassemia major (TM) is one of the most prevalent inherited hemoglobinopathies in Pakistan. It has one of the highest prevalence of transfusion-dependent TM patients globally, with an estimated greater than 100,000 active cases. Blood transfusions (BT) are essential in the management of severe TM; it is critical to have a safe BT to reduce the risk of transfusion transmissible infections (TTIs). Frequent blood transfusions in these patients increase their risk of acquiring TTIs compared to the general population. We performed a systematic literature search to identify studies related to the TTIs and transfusion-related infections in Pakistan from January 1, 2010, to January 31, 2020. The search was conducted using PubMed and PakMediNet, with initial search retrieved 981 studies. Among these, 166 studies met the inclusion criteria, and only 14 studies met the final criteria for qualitative synthesis. Analysis of 14 studies (n = 3786) showed the seroprevalence of hepatitis B virus (HBV) of 3.13% (0.66% to 7.4%) and hepatitis C virus (HCV) of 26% (5.56% to 68.2%). There were only two studies that reported HIV seroprevalence of 0% and 0.5% (n = 6). The rate of seropositivity for HBV and HCV was directly related to the number of transfusions, higher ferritin levels, and older age groups. There was an increase in the HCV rate with the increasing age of patients. Thalassemia patients, who were older than ten years of age, had an HCV rate of 22% compared to only 8.4% in patients younger than ten years of age. A comparison of HCV in healthy donors vs. thalassemia patients showed a rate of 1.9% vs. 13.1% for TM patients. The majority of the patients were males (51% to 88%). The seroprevalence of TTIs was higher in males than in females (73.4% vs. 26.6%). On average, a single TM patient is exposed to at least 17 different donors annually, requiring 1-2 transfusions every month. Our study highlights that the prevalence of transfusion-transmitted infections, especially HCV, is alarmingly higher (26%) in the TM population than in the general population. There is limited data regarding the prevalence of HIV, syphilis, and malaria in this population. This is mainly due to a fragmented system of blood transfusion, weak regulations, and lower rates of voluntary blood donations. These findings warrant better health measures to improve the blood donation system and specialized care for TM patients.
重型β地中海贫血(TM)是巴基斯坦最常见的遗传性血红蛋白病之一。在全球范围内,该国依赖输血的TM患者患病率最高,估计活跃病例超过10万例。输血在重型TM的治疗中至关重要;确保安全输血以降低输血传播感染(TTI)的风险至关重要。与普通人群相比,这些患者频繁输血会增加感染TTI的风险。我们进行了系统的文献检索,以确定2010年1月1日至2020年1月31日期间巴基斯坦与TTI和输血相关感染的研究。检索使用了PubMed和PakMediNet,初步检索到981项研究。其中,166项研究符合纳入标准,只有14项研究符合定性综合的最终标准。对14项研究(n = 3786)的分析显示,乙肝病毒(HBV)血清阳性率为3.13%(0.66%至7.4%),丙肝病毒(HCV)血清阳性率为26%(5.56%至68.2%)。只有两项研究报告HIV血清阳性率分别为0%和0.5%(n = 6)。HBV和HCV的血清阳性率与输血次数、铁蛋白水平升高以及年龄较大的人群直接相关。HCV感染率随患者年龄增长而增加。10岁以上的地中海贫血患者HCV感染率为22%,而10岁以下患者仅为8.4%。健康献血者与地中海贫血患者的HCV感染率比较显示,TM患者为13.1%,而健康献血者为1.9%。大多数患者为男性(51%至88%)。男性的TTI血清阳性率高于女性(73.4%对26.6%)。平均而言,一名TM患者每年至少接触17名不同的献血者,每月需要输血1 - 2次。我们的研究强调,TM人群中输血传播感染的患病率,尤其是HCV,比普通人群高得多(26%),令人担忧。关于该人群中HIV、梅毒和疟疾患病率的数据有限。这主要是由于输血系统分散、监管薄弱以及自愿献血率较低。这些发现需要采取更好的卫生措施来改善献血系统,并为TM患者提供专门护理。